Journal
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 94, Issue 3, Pages 423-427Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2008.001024
Keywords
CD20 antigen; mutation; DLBCL; R-CHOP
Categories
Funding
- Terry Fox Foundation [016003]
- National Cancer Institute of Canada [019005]
- Michael Smith Foundation for Health Research [ST-PDF-01793]
- Canadian Institute of Health Research [STP-53912]
- Roche Canada
Ask authors/readers for more resources
Rituximab binds an epitope on the CD20 antigen, encompassed in exon 5 of the MS4A1 gene. We sequenced this region and correlated the presence of mutations with CD20 protein expression and response to R-CHOP in patients with diffuse large B-cell lymphoma: 264 diagnostic biopsies and 15 biopsies taken at the time of relapse were successfully sequenced. CD20 mutations involving the rituximab epitope were detected in only 1/264 (0.4%) and 1115 (6%) of the biopsies taken at diagnosis and relapse; respectively. No polymorphic sequence variants were detected in this region. Three patients had malignant cells that were CD20 protein-positive at diagnosis but CD20-negative at relapse. Thus, CD20 mutations involving the rituximab epitope are rare in both de novo and relapsed diffuse large B-cell lymphoma, and do not represent a significant cause of R-CHOP resistance. CD20 protein-negative relapses occur after R-CHOP therapy but their clinical relevance is unknown.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available